CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 268 enrolled
Drug / intervention
Venlafaxine XR +1 moredrug
Likely dose
Venlafaxine XR 75–225 mg once dailyAI-extracted
Key inclusion· 5
  • ✓Generalized Anxiety Disorder diagnosis confirmed by structured interview
  • ✓Hamilton Anxiety Scale score ≥18
  • ✓Clinical Global Impressions Severity Scale score ≥4
  • ✓Hamilton Depression Scale score ≤18
Key exclusion· 7
  • ✕Hypersensitivity or allergy to venlafaxine XR
  • ✕History of seizures
  • ✕Major depressive episode in prior 6 months
  • ✕History of psychotic illness, bipolar disorder, or dementia

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00183274
NCT00183274Phase 4Completed
CompareCT.gov

Short-term Versus Long-term Treatment in Generalized Anxiety Disorder

University of Pennsylvania·interventional·Posted Sep 16, 2005·Updated Jan 16, 2017

In Brief

A Phase 4 clinical trial evaluating Venlafaxine XR and Placebo for Anxiety Disorders. Completed, enrolled 268 participants across 1 site.

Detailed Summary

This study will assess the effectiveness of venlafaxine XR, randomized to either venlafaxine XR or placebo in preventing the relapse of generalized anxiety disorder after 6 months of treatment versus 12 months of treatment.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAnxiety Disorders
CountriesUnited States
CollaboratorsNational Institute of Mental Health (NIMH)

Timeline

Phase 4CompletedFinished
200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedSep 16, 2005
Enrollment StartJan 1, 2004
Primary CompletionSep 1, 2009
TodayJul 2, 2026
Enrollment to primary: 5.7 yearsPosted 20.8 years ago

Interventions

Venlafaxine XRdrug

Six month intervention of Venlafaxine XR treatment with flexible range of 75 to 225 mg/d

Placebodrug

six month intervention with placebo drug